[Sar9,Met(O2)11]-Substance P; 纯度: 99.91%
[Sar9,Met(O2)11]-Substance P 是一种选择性的速激肽 NK1 受体激动剂。
[Sar9,Met(O2)11]-Substance P Chemical Structure
CAS No. : 110880-55-2
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
1 mg | ¥990 | In-stock | |
5 mg | ¥3900 | In-stock | |
10 mg | ¥6900 | In-stock | |
25 mg | ¥14000 | In-stock | |
50 mg | ; | 询价 | ; |
100 mg | ; | 询价 | ; |
* Please select Quantity before adding items.
[Sar9,Met(O2)11]-Substance P 相关产品
bull;相关化合物库:
- Bioactive Compound Library Plus
- Peptide Library
生物活性 |
[Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist. |
IC50 Target |
NK1 receptor[1] |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
[Sar9,Met(O2)11]-Substance P and septide (10-100 pmol per rat, i.c.v.) are equipotent in increasing mean arterial blood pressure (MAP) and heart rate (HR), yet they have dissimilar time-course. Both agonists increase dose-dependently face washing and sniffing while [Sar9,Met(O2)11]-Substance P is the sole to produce grooming[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||
分子量 |
1393.66 |
||||||||||||||||
Formula |
C64H100N18O15S |
||||||||||||||||
CAS 号 |
110880-55-2 |
||||||||||||||||
Sequence |
Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-{Sar}-Leu-Met[O2]-NH2 |
||||||||||||||||
Sequence Shortening |
RPKPQQFF-{Sar}-LM[O2]-NH2 |
||||||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||||||
储存方式 |
|
||||||||||||||||
溶解性数据 |
In Vitro:;
H2O : 50 mg/mL (35.88 mM; Need ultrasonic) 配制储备液
*
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
||||||||||||||||
参考文献 |
|
Kinase Assay [1] |
Rats initially receive an i.c.v. injection of artificial cerebrospinal fluid (aCSF; 1 μl) followed 60 min later by a single dose of either [Sar9,Met(O2)11]-Substance P (10 pmol (n=9), 25 pmol (n=9), 65 pmol (n=8) or 100 pmol (n=8)) or septide (10 pmol (n=12), 25 pmol (n=9), 65 pmol (n=6) or 100 pmol (n=6)) to construct a complete dose-response curve. Each rat is selected randomly and injected with only one of the two agonists for the remainder of the protocol. Increasing doses of [Sar9,Met(O2)11]-Substance P or septide are given at 24 h intervals on day 1 (10 pmol), day 2 (25 pmol), day 3 (65 pmol) and day 4 (100 pmol). Control rats (n=18) receive only the vehicle (aCSF) each day of experiment. Peptides are administered in a volume of 1 μL of vehicle followed by 5 μL flush volume of aCSF which corresponds to the void volume of the catheter. Each dose is calculated per rat in 1 μL solution[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
参考文献 |
|